Niche Specialization Array Biostatistics operates as a specialized full-service biostatistical and statistical programming CRO within the pharmaceutical industry, presenting a focused opportunity to target biopharmaceutical companies seeking expert statistical services for clinical trials.

Acquisition Momentum Following its acquisition by CATO SMS in September 2020, Array Biostatistics is part of a larger portfolio of clinical research solutions, indicating potential for integrated service offerings and increased market reach to prospective clients.

Growth Potential With revenue below 1 million dollars and a relatively small team of 11-50 employees, Array offers potential for growth and expansion, especially by leveraging its niche expertise to attract mid-sized biotech firms or early-stage pharmaceutical companies.

Tech Foundations Utilizing a modern tech stack including WordPress, MySQL, and Google Analytics, Array is positioned to enhance digital engagement and outreach efforts, offering opportunities to improve online visibility and lead generation for sales initiatives.

Market Opportunity Compared to larger competitors like IQVIA and Parexel with extensive service portfolios and vast resources, Array’s specialized focus allows for personalized outreach to boutique biotech firms and emerging companies seeking tailored statistical support.